Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.194 EUR | +4.93% | +18.54% | +24.86% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.1M 20.42M | Sales 2025 * | 343M 31.65M 29.26M | Capitalization | 2.22B 205M 190M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.89M -62.76M | Net income 2025 * | -712M -65.77M -60.79M | EV / Sales 2024 * | 11.3 x |
Net Debt 2024 * | 474M 43.78M 40.47M | Net Debt 2025 * | 733M 67.74M 62.62M | EV / Sales 2025 * | 8.62 x |
P/E ratio 2024 * |
-3.05
x | P/E ratio 2025 * |
-3.62
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 week | +18.54% | ||
Current month | +24.35% | ||
1 month | +16.09% | ||
3 months | -2.06% | ||
6 months | +45.23% | ||
Current year | +24.86% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change |
---|---|---|
24-05-14 | 3.194 | +4.93% |
24-05-13 | 3.044 | +12.32% |
24-05-10 | 2.71 | +2.34% |
24-05-09 | 2.648 | -0.38% |
24-05-08 | 2.658 | +6.07% |
Real-time BOERSE MUENCHEN, May 14, 2024 at 01:13 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.08% | 48.16B | |
-1.22% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.11% | 25.59B | |
-22.89% | 18.96B | |
+7.94% | 12.92B | |
+29.01% | 12.03B | |
-1.89% | 11.77B |
- Stock Market
- Equities
- HNSA Stock
- 24H Stock